Company intelligence / Profile preview
OPKO Biologics
Israelopkobiologics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OPKO Biologics develops bio-better, long-acting therapeutic proteins and peptides. Its lead programs are in preclinical or pending clinical stage, targeting endocrine and metabolic diseases such as obesity, growth hormone deficiency, and rare disease indications. The company’s novel engineered peptides and proteins have demonstrated improved pharmacokinetics compared to standard biologics in earlier R&D.
- Therapeutic areas
- NeurologyEndocrinologyGastroenterology
- Modalities
- ProteinPeptidesSynthetic peptideBiologic
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on OPKO Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPKO Biologics.